Consumer protection, advertising and unapproved stem cell treatments

Written by Regenerative Medicine

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled ‘Regulating the advertising and promotion of stem cell therapies‘ from Barbara von Tigerstrom [1].

Clinics that offer unapproved stem cell treatments are growing in number around the world. These unproven therapies are often advertised by clinics directly to potential customers with advertisements and information that many people consider misleading. Consumer protection laws could assist in addressing and restricting how unproven stem cell therapies are marketed, but also face limitations due to the international scope of the stem cell market.

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: 
https://www.eurostemcell.org/regenerative-medicine-society/consumer-protection-advertising-and-unapproved-stem-cell-treatments

The full original article can be accessed here: 
https://www.futuremedicine.com/doi/10.2217/rme-2017-0057

References

[1] von Tigerstrom BRegulating the advertising and promotion of stem cell therapies. Regen. Med. 12(7), 815—826 (2017).